Juan P. Alderuccio, MD, discusses data from loxcastuximab tesirine plus rituximab in high-risk, relapsed/refractory follicular lymphoma.
Juan P. Alderuccio, MD
Advertisement
Juan P. Alderuccio, MD, is an associate professor of medicine and clinical site disease group leader in the Lymphoma Section at Sylvester Comprehensive Cancer Center, University of Miami Health System.
Articles by Juan P. Alderuccio, MD
Juan Pablo Alderuccio, MD, discusses the combination of loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma.
Juan P. Alderuccio, MD, assistant professor of clinical medicine at Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the use of proteasome inhibitors in the frontline treatment of patients with multiple myeloma.
Advertisement
Latest Updated Articles
Dr. Alderuccio on the Use of Proteasome Inhibitors in Frontline MyelomaPublished: April 17th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma
4
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
5